Alector, Inc.
Company Stats
- Market Cap
- $206.6M
- as of Sep 30, 2026
- Shares Outstanding
- 111.7M
- Free Float
- 76.6%
Income Statement
- Revenue
- $21.0M
- Operating Income
- -$156.0M
- Net Income
- -$142.9M
- EBITDA
- -$150.3M
- Revenue Growth, 3Y
- -46.0%
- FCF Margin, 3Y Avg
- -432.2%
- FCF Margin, Worst Year
- -874.7%
Cash Flow
- Free Cash Flow
- -$184.1M
- FCF Yield
- -89.1%
- Owner FCF Yield
- -102.0%
Balance Sheet
- Cash & Equivalents
- $65.8M
Returns & Capital
- SBC, 3Y Avg
- $36.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $21.0M | -$184.1M | -874.7% |
| FY2024 | $100.6M | -$231.2M | -229.9% |
| FY2023 | $97.1M | -$186.5M | -192.1% |
| FY2022 | $133.6M | -$24.4M | -18.3% |
| FY2021 | $207.1M | $295.3M | 142.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 28, 2026
Deals
Alector Licenses AL050 to Genentech for $100 Million Upfront
October 27, 2026
Deals
Alector Grants Genentech Rights to AL050
October 26, 2026
Deals
Alector to License AL050 to Genentech for $100 Million Upfront
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
Alector Licenses AL050 to Genentech for $100 Million Upfront
October 27, 2026
Deals
Alector Grants Genentech Rights to AL050
October 26, 2026
Deals
Alector to License AL050 to Genentech for $100 Million Upfront
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back